Back
Telesis Bio 10K Form
Sell
20
TBIO
Telesis Bio
Last Price:
0.93
Seasonality Move:
-0.31%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-10 | 10Q | TBIO/Telesis Bio Quarterly |
| 2023-11-13 | 10Q | TBIO/Telesis Bio Quarterly |
| 2023-08-11 | 10Q | TBIO/Telesis Bio Quarterly |
| 2023-05-12 | 10Q | TBIO/Telesis Bio Quarterly |
| 2022-11-09 | 10Q | TBIO/Telesis Bio Quarterly |
| 2022-08-10 | 10Q | TBIO/Telesis Bio Quarterly |
Receive TBIO News And Ratings
See the #1 stock for the next 7 days that we like better than TBIO
TBIO Financial Statistics
Sales & Book Value
| Annual Sales: | $27.51M |
|---|---|
| Cash Flow: | $-5.43M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-11.59 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -30.78000 |
|---|---|
| Net Income (TTM): | $-49.54M |
| Gross Margin: | $16.95M |
| Return on Equity: | -151.32% |
| Return on Assets: | -61.01% |
Telesis Bio Earnings Forecast
Key Telesis Bio Financial Ratios
- The Gross Profit Margin over the past 4 years for TBIO is 61.62%.
- The Selling, General & Administrative Expenses for TBIO have been equal to 125.79% of Gross Profit Margin.
- The Research & Development expenses have been 63.60% of Revenue.
- The Interest Expense is -6.51% of Operating Income.
- The Net Earning history of TBIO is -173.49% of Total Revenues.
- Per Share Earnings over the last 4 years have been positive in 2 years.
Telesis Bio Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Industry: | Life Sciences Tools & Services |
| Sector: | Health Care |
| Current Symbol: | TBIO |
| CUSIP: | 89374L |
| Website: | telesisbio.com |
Debt
| Debt-to-Equity Ratio: | 0.53 |
|---|---|
| Current Ratio: | 1.89 |
| Quick Ratio: | 1.44 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
TBIO Technical Analysis vs Fundamental Analysis
Sell
20
Telesis Bio (TBIO)
is a Sell
Is Telesis Bio a Buy or a Sell?
-
Telesis Bio stock is rated a Sell
The current Telesis Bio [TBIO] share price is $0.93. The Score for TBIO is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.